Novavax Inc (NVAX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $11.19
• Market Cap: $1.55B
• P/E Ratio: 4.74
• EPS: $2.01
• 52-Week High: $10.64
• 52-Week Low: $5.01

Market Sentiment

Novavax Inc currently has a Bullish sentiment score of 0.20.

About Novavax Inc

Novavax, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the research and development of innovative vaccines targeting serious infectious diseases. Leveraging its proprietary protein-based nanoparticle technology, Novavax has cultivated a robust pipeline, notably including its advanced COVID-19 vaccine candidate, which has received considerable attention amid the ongoing global health crisis. The company's commitment to addressing pressing public h...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Novavax Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does NVAX pay dividends?

Novavax Inc (NVAX) does not currently pay a regular dividend.

What is NVAX's P/E ratio?

Novavax Inc has a price-to-earnings (P/E) ratio of 4.74.

What is NVAX's market cap?

Novavax Inc (NVAX) has a market capitalization of $1.55B with a current stock price of $11.19.